- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NICE Turns Around to Support the Use of Celgene's Revlimid
The cost regulator for the NHS in England and Wales has said that Celgene's Revlimid should be an option for treating patients with a particular form of myelodysplastic syndromes.
In new final draft guidance, the National Institute for Health and Care Excellence (NICE) has recommended use of Revlimid (lenalidomide) in a specific type of MDS that is characterised by a chromosomal abnormality called an isolated deletion 5q cytogenetic abnormality. Currently, the main treatment option for people with this kind of MDS is best supportive care including regular blood transfusions.
In earlier draft guidances published this May and in June last year, NICE had not backed Revlimid in this use because, while the Institute’s appraisal committee had found it to be an effective therapy, the data provided by Celgene showed uncertainty about whether it actually extended lives. The June 2013 draft guidance had also opened a consultation.
Link to the original report: http://bit.ly/1pf6gSi
Source: PharmaTimes
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
